investors.merck.comInvestor relations - Merck.com

everythingCloseCompany Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact investing Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct & compliance Diversity & inclusion Policies & positions Business development & licensing Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overview Areas of focus Oncology Vaccines Infectious diseases Cardio-metabolic disorders Immunology Neuroscience Pipeline Meet our scientists Discovery & development R&D locations Clinical trials Clinical trials overview Find a trial Diversity in clinical trials Products Products list Safety data sheets Product patents Merck authorized distributors Patients Patients overview Patient support programs Play an active role in your health care Careers Careers Search jobs Our divisions Research & development Manufacturing & supply Human Health Animal Health Global support functions Veterans Student opportunities Compensation & benefits How we hire MSD Careers Events Talent community Investors Investors overview Events & presentations Financial information Financial information overview SEC filings Stock information Investor resources Investor resources overview Organon resources Media Media overview News releases Company statements Media library & contacts Company fact sheet Who we are Learn more Contact us Worldwide Countries outside of the United States and Canada. What can we help you find? Search for: Investor relations Our science-led strategy is key to delivering long-term value for patients, employees and shareholders. NYSE: MRK May 14, 2024 3:14 am ET Delayed at least 20 minutes View stock information Latest news, events & financials News Events & presentations Financials May 13, 2024 Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma May 9, 2024 Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent May 8, 2024 Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers View all 4 May 15, 2024 Webcast Merck & Co., Inc. at the Bank of America Securities 2024 Healthcare Conference Icons / 16 / Search Created with Sketch. Add to Calendar Apple Calendar Google Calendar Outlook Calendar iCalendar Icons / 16 / Microphone Created with Sketch. Webcast May 28, 2024 Webcast Merck & Co., Inc. 2024 Annual Meeting of Shareholders Icons / 16 / Search Created with Sketch. Add to Calendar Apple Calendar Google Calendar Outlook Calendar iCalendar Icons / 16 / Microphone Created with Sketch. Webcast June 03, 2024 Investor Merck & Co., Inc. Investor Event at ASCO 2024 Icons / 16 / Search Created with Sketch. Add to Calendar Apple Calendar Google Calendar Outlook Calendar iCalendar Icons / 16 / Microphone Created with Sketch. Webcast July 30, 2024 Earnings Merck & Co., Inc. Q2 2024 Earnings Call Icons / 16 / Search Created with Sketch. Add to Calendar Apple Calendar Google Calendar Outlook Calendar iCalendar View all 1Q24 Merck Earnings Announcement PDF 1Q24 Merck Other Financial Disclosures PDF View all Merck & Co., Inc. Q1 2024 Earnings Call Dial: (888) 847-9708 (U.S. Toll-Free) or (630) 395-0358 (International) Access Code: 4164932 Icons / 16 / Microphone Created with Sketch. Webcast 1Q24 Merck Earnings Presentation 1Q24 Merck Earnings Announcement 1Q24 Merck Other Financial Disclosures Transcript Form 10-Q 1Q24 Other Financial Disclosures (Excel) 1Q24 Prepared Remarks See full agenda Our pipeline shows our relentless pursuit of the next breakthrough. Explore our pipeline Phase II programs 80+ Phase III programs 30+ Under review 10+ Our leadership Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy. Leadership Sustainability Supporting the future of our business and the health and well-being of patients, people and communities around the world. Download our Impact Report 2022/2023 Download our Sustainability financing documents: 2021 Sustainability financing framework Second-party opinion (SPO) on the bond framework 2023 Sustainability bond allocation report 2022 Sustainability bond allocation report We’re led by our science We follow the science to our next breakthrough, leaving no stone unturned. View our stories Innovation Our Q1 2024 earnings report Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing […] Read more Next: Our Q1 2024 earnings report Innovation Celebrating the opening of our latest state-of-the-art facility The FLEx Center will help us continue to harness the power of leading-edge science with agility Read more Next: Celebrating the opening of our latest state-of-the-art facility Innovation Why we’re expanding and investing in our research and discovery efforts Our commitment to innovation helps ensure a brighter future for patients everywhere Read more Next: Why we’re expanding and investing in our research and discovery efforts Innovation Our Q1 2024 earnings report Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing […] Read more Next: Our Q1 2024 earnings report Innovation Celebrating the opening of our latest state-of-the-art facility The FLEx Center will help us continue to harness the power of leading-edge science with agility Read more Next: Celebrating the opening of our latest state-of-the-art facility Innovation Why we’re expanding and investing in our research and discovery efforts Our commitment to innovation helps ensure a brighter future for patients everywhere Read more Next: Why we’re expanding and investing in our research and discovery efforts Previous Next Sign up for email alerts Receive company news, updates and other information Unsubscribe from email alerts For questions, please contact our team. Contact investor relations (732) 594-1468 investor_relations@merck.com Related links Who we are We aspire to be the premier research-intensive biopharmaceutical company. Financial information Find information about our quarterly reports, annual reports & proxy and SEC filings Stock information See stock quotes and charts on a monthly, quarterly or yearly basis Connect with us on social For patients and health care professionals MerckHelps Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients Merck Access Program Information about insurance coverage and financial assistance options for eligible patients Clinical trials Information about insurance coverage and financial assistance options for eligible patients Merck Manuals Medical information source covering thousands of topics in all fields of medicine Sustainability Impact Report Reporting on our commitment to operating responsibly to benefit society Merck for Mothers An initiative to create a world where no woman has to die giving life About Merck Merck Animal Health The global animal health business unit of Merck Health Plan - Transparency in Coverage In compliance with the Consolidated Appropriations...